Norwegian company iSentio, maker of the web-based sequence analysis software RipSeq, has a new chairman of the board and investors.
Siri Fürst has been named chairman of the board. Fürst has held managerial positions at Hafslund, Hafslund Nycomed, and Nycomed Pharma and served as CEO at DiaGenic. In 2005 she joined Considium Consulting Group. She holds a degree in economics from the Norwegian School of Economics and Business Administration.
Norwegian seed capital fund company Sarsia Seed has become a new investor and will hold two positions on iSentio's board. Sarsia Seed invests in early-phase technology companies within the energy, cleantech, and life science sectors.
Biotech company Nodality has appointed Greg Critchfield to its board of directors. Critchfield recently retired as president of Myriad Genetic Laboratories, where he launched seven diagnostics products. Prior to Myriad, he served as Quest Diagnostics' chief medical and science officer.
He holds a BS in microbiology with a minor in chemistry from Brigham Young University, an MD from the University of Utah, and an MS in biophysical sciences from the University of Minnesota.